公开(公告)号：US20240350516A1

公开(公告)日：2024-10-24

申请号：US18759260

申请日：2024-06-28

Applicant: Azura Ophthalmics Ltd.

Inventor： Yair ALSTER ,  Omer RAFAELI ,  Kirsten Angela MACFARLANE ,  Cary REICH ,  Shimon AMSELEM ,  Doron FRIEDMAN

IPC: A61K31/60 ,  A61K8/22 ,  A61K8/23 ,  A61K9/00 ,  A61K9/06 ,  A61K31/122 ,  A61K31/17 ,  A61K31/19 ,  A61K31/327 ,  A61K31/4015 ,  A61K31/555 ,  A61K33/04 ,  A61K35/04

CPC classification number: A61K31/60 ,  A61K8/22 ,  A61K8/23 ,  A61K9/0048 ,  A61K9/06 ,  A61K31/122 ,  A61K31/17 ,  A61K31/19 ,  A61K31/327 ,  A61K31/4015 ,  A61K31/555 ,  A61K33/04 ,  A61K35/04 ,  A61K9/0014

Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

公开(公告)号：US12115139B2

公开(公告)日：2024-10-15

申请号：US15998013

申请日：2018-08-15

Applicant: Todd Alan Weinfield

Inventor： Todd Alan Weinfield

IPC: A61K31/14 ,  A61K9/00 ,  A61K31/095 ,  A61K31/155 ,  A61K31/17 ,  A61K31/45 ,  A61P31/10

CPC classification number: A61K31/14 ,  A61K9/0014 ,  A61K31/095 ,  A61K31/155 ,  A61K31/17 ,  A61K31/45 ,  A61P31/10 ,  A61K2300/00

Abstract: A method of treating nail infections by using keratolytic, quaternary ammonium chloride, biguanide compounds and water heated above nail temperature.

公开(公告)号：US20240335429A1

公开(公告)日：2024-10-10

申请号：US18293684

申请日：2022-08-02

Applicant: National University of Singapore ,  Beth lsrael Deaconess Medical Center, Inc.

Inventor： Le Kim Anh VU ,  Bee Hui LIU ,  Daniel Geoffrey TENEN

IPC: A61K31/433 ,  A61K31/17 ,  A61K31/381 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4545 ,  A61K31/47 ,  A61P35/00

CPC classification number: A61K31/433 ,  A61K31/17 ,  A61K31/381 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4545 ,  A61K31/47 ,  A61P35/00

Abstract: Provided is the use of compounds of Formula I, as well as certain specific compounds, or a pharmaceutically acceptable salt, solvate or derivative thereof, in the preparation of a medicament to treat cancer, such as liver cancer (e.g. hepatocellular carcinoma) and lung cancer.

公开(公告)号：US20240319209A1

公开(公告)日：2024-09-26

申请号：US18578165

申请日：2022-07-15

Applicant: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  ETABLISSEMENT FRANÇAIS DU SANG (EFS) ,  UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE

Inventor： Véronique BAUDIN-CREUZA ,  Frédéric GALACTEROS ,  Corinne VASSEUR

IPC: G01N33/68 ,  A61K31/17 ,  A61P7/06

CPC classification number: G01N33/6893 ,  A61K31/17 ,  A61P7/06 ,  G01N2470/04 ,  G01N2800/22 ,  G01N2800/52

Abstract: The Alpha haemoglobin-stabilising protein (AHSP) is a key chaperone molecule synthesised in red blood cell (RBC) precursors. In this study, the inventors have developed a sandwich ELISA method which allows the quantification of AHSP protein in RBCs of normal subjects and in sickle cell anaemia (SCA) patients treated or untreated by hydroxycarbamide. AHSP was significantly more abundant in untreated SCA patients than in controls (p

公开(公告)号：US20240307537A1

公开(公告)日：2024-09-19

申请号：US18451632

申请日：2023-08-17

Applicant: Omeros Corporation

Inventor： Michael Cicirelli ,  Neil S. Cutshall ,  Gregory A. Demopulos ,  George A. Gaitanaris ,  Marc A. Gavin ,  Alexander Gragerov ,  Thomas L. Little ,  Rene Onrust

IPC: A61K39/00 ,  A61K31/17 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4409 ,  A61K31/473 ,  A61K31/495 ,  A61K31/496 ,  A61K31/502 ,  A61K31/506 ,  A61K31/519 ,  A61K31/522 ,  A61K31/53 ,  A61K31/55 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574

CPC classification number: A61K39/4643 ,  A61K31/17 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4409 ,  A61K31/473 ,  A61K31/495 ,  A61K31/496 ,  A61K31/502 ,  A61K31/506 ,  A61K31/519 ,  A61K31/522 ,  A61K31/53 ,  A61K31/55 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  G01N33/57488 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/76

Abstract: This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).

公开(公告)号：US20240299322A1

公开(公告)日：2024-09-12

申请号：US18424930

申请日：2024-01-29

Applicant: LANTERN PHARMA INC.

Inventor： Aditya Kulkarni ,  Jianli Zhou ,  Kishor Bhatia

IPC: A61K31/17 ,  A61K31/122 ,  A61K31/337 ,  A61K31/502 ,  A61K31/5025 ,  A61K33/243 ,  A61P35/00

CPC classification number: A61K31/17 ,  A61K31/122 ,  A61K31/337 ,  A61K31/502 ,  A61K31/5025 ,  A61K33/243 ,  A61P35/00

Abstract: A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a PARP inhibitor or an analog, derivative, or a pharmaceutically acceptable salt thereof. Compositions and kits of the same are included herein.

公开(公告)号：US20240254077A1

公开(公告)日：2024-08-01

申请号：US18596300

申请日：2024-03-05

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Jeanine D'Armiento

IPC: C07C275/10 ,  A61K31/17 ,  A61K31/18 ,  C07C311/04 ,  C07C311/17

CPC classification number: C07C275/10 ,  A61K31/17 ,  A61K31/18 ,  C07C311/04 ,  C07C311/17

Abstract: The present invention relates to the treatment of chronic obstructive pulmonary disease (COPD). More specifically, embodiments of the invention provide a pharmaceutical carrier and a compound that inhibit the induction of MMP-1 expression by cigarette smoke.

公开(公告)号：US20240238227A1

公开(公告)日：2024-07-18

申请号：US18136313

申请日：2023-04-18

Applicant: WOOSHIN LABOTTACH CO., LTD.

Inventor： Taek Soo NAM

IPC: A61K31/17 ,  A61K9/06 ,  A61K9/70 ,  A61K31/194 ,  A61K31/4188 ,  A61K47/32 ,  A61P31/10

CPC classification number: A61K31/17 ,  A61K9/06 ,  A61K9/7023 ,  A61K31/194 ,  A61K31/4188 ,  A61K47/32 ,  A61P31/10

Abstract: A pharmaceutical composition in the form of a hydrogel for preventing or treating onychomycosis or relieving ingrown toenail pain, the pharmaceutical composition containing urea, biotin, fumaric acid, 1,3-butylene glycol, a gel-forming polymer, a crosslinking agent, and 45 to 60 wt % of water, and having keratolytic and moisture-retention abilities to provide a hydrated environment for fingernails, toenails and surrounding tissues.

公开(公告)号：US20240182424A1

公开(公告)日：2024-06-06

申请号：US18317195

申请日：2023-05-15

Applicant: FibroGen, Inc.

Inventor： Stephen J. KLAUS ,  Christopher J. MOLINEAUX ,  Thomas B. NEFF ,  Volkmar GUENZLER-PUKALL ,  Robert C. STEPHENSON ,  Todd W. SEELEY ,  Ingrid LANGSETMO PAROBOK

IPC: C07D217/24 ,  A61K31/00 ,  A61K31/165 ,  A61K31/17 ,  A61K31/395 ,  A61K31/472 ,  C07C275/40

CPC classification number: C07D217/24 ,  A61K31/00 ,  A61K31/165 ,  A61K31/17 ,  A61K31/395 ,  A61K31/472 ,  C07C275/40

Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.

公开(公告)号：US11974972B1

公开(公告)日：2024-05-07

申请号：US18388696

申请日：2023-11-10

Applicant: Joong Ho Moon ,  Michelle Miranda

Inventor： Joong Ho Moon ,  Michelle Miranda

IPC: A61K8/43 ,  A61K31/133 ,  A61K31/155 ,  A61K31/17 ,  A61K31/277 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/498 ,  A61K31/5377 ,  A61P31/04 ,  A61P31/06 ,  C07C279/12 ,  C07D295/215 ,  C08G65/00 ,  C08G71/02

CPC classification number: A61K31/17 ,  A61K31/133 ,  A61K31/277 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/498 ,  A61K31/5377 ,  A61P31/06 ,  C07C279/12 ,  C07D295/215 ,  C08G65/00 ,  C08G71/02 ,  C07C2601/16

Abstract: The subject invention provides oligo(carbamoylated guanidine)s (OCGs) having fast and selective mycobactericidal effects via disruption of the mycobacterial membrane potential. OCGs also potentiates bedaquiline, an oxidative phosphorylation-targeting anti-TB drug. The combination of OCG and anti-TB drug can be used as an effective therapy for treating tuberculosis.